This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection

Sponsored by University of Siena

About this trial

Last updated 8 years ago

Study ID

IGRAManPed2014

Status

Unknown status

Type

Observational

Placebo

No

Accepting

18-75 Years
1 to 17 Years
All
All

Trial Timing

Ended 5 years ago

What is this trial about?

The aim of this project is to analyze the potential contribution of IGRA test QuantiFERON-TB Gold In Tube test (QTF-GIT, Cellestis Limited, Carnegie, Victoria, Australia) in the diagnosis of tuberculosis (TB - active or latent) in pediatric subjects (0 and 17 year)s recently exposed to infection (indicated as "contacts") or with clinical suspicion of active TB, and to compare the results obtained with those of the TuberculinSkin Test (TST; gold standard). The project is expected to enroll up to 50 pediatric patients over a 4-year study. Children with access to Ambulatory structures or hospitalized at University Infectious Diseases Clinic or Pediatric Clinic, University Hospital of Siena, or with access to Ambulatory or hospitalized at Pediatric Clinic USL 9 Grosseto will be enrolled. Once obtained the informed consent of patients' parents or legal guardians, patients will be enrolled. The doctor will administer a clinical-anamnestic questionnaire, relative to the country of birth and residence, date of arrival in Italy and any stays in the country of origin (in case of foreign patient), travels abroad, risk factors for infectious diseases, type of contact with any index case, previous vaccination with BCG, date and outcome of the TST, clinical symptoms and signs suggestive of active TB, report of any instrumental investigation. Together with the collection of blood samples for routine purposes, an additional blood sample will be taken so to run IGRA test. Also patients for whom their medical doctor will independently order to run QTF-GIT test as necessary tool for the clinical diagnosis of TB will be included in the study. A retrospective analysis will be performed on patient pertaining to participant Clinics, from 1 January 2012 to 31 May 2015. Such analysis will be performed on those patients for which their medical doctor requested both intradermal Mantoux and IGRA test. Expected results: - estimation of concordance between QuantiFERON-TB Gold In Tube and TST in pediatric patients exposed to TB, with or without latent TB infection - Evaluation of the sensitivity of the test QTF-GIT in patients with active tuberculosis disease - Evaluation of specificity of testQTF-GIT in not infected patients - Evaluation on the possible use of QTF-GIT, together with TST, to improve the diagnosis of tuberculosis latent or active infection in pediatric subjects. - Evaluation of the possible diagnostic use of QTF-GIT in the child <5 years.

What are the participation requirements?

Yes

Inclusion Criteria

- Age between 0 to 17 years

- Willingness to provide informed consent (parents or legal guardians)

- Contact with TB case and/or clinical suspect of active TB

No

Exclusion Criteria

- Acquired or congenital immune deficiencies

- Oncohematologic diseases